An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT ID: NCT00932893

Last Updated: 2017-01-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

347 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-02341066

Group Type EXPERIMENTAL

PF-02341066

Intervention Type DRUG

PF-02341066, 250 mg BID will be administered orally on a continuous schedule

Pemetrexed or Docetaxel

Investigator selection of either pemetrexed or docetaxel as the active comparator

Group Type ACTIVE_COMPARATOR

Pemetrexed

Intervention Type DRUG

Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle

Docetaxel

Intervention Type DRUG

Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-02341066

PF-02341066, 250 mg BID will be administered orally on a continuous schedule

Intervention Type DRUG

Pemetrexed

Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle

Intervention Type DRUG

Docetaxel

Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically or cytologically proven diagnosis of non-small cell lung cancer
* positive for the ALK fusion gene (test provided by a central laboratory)
* must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
* tumors must be measurable

Exclusion Criteria

* prior treatment with PF-02341066
* current treatment in another clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Research, Winthrop Rockefeller Cancer Institute

Little Rock, Arkansas, United States

Site Status

Comprehensive Blood and Cancer Center

Bakersfield, California, United States

Site Status

Tower Cancer Research Foundation

Beverly Hills, California, United States

Site Status

Tower Hematology Oncology Medical Group

Beverly Hills, California, United States

Site Status

UCSD Medical Center -La Jolla

La Jolla, California, United States

Site Status

Moores UC San Diego Cancer Center

La Jolla, California, United States

Site Status

Drug Shipping Address: [IRB# 10-001530] Ronald Reagan UCLA

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

UCLA Hematology Oncology

Los Angeles, California, United States

Site Status

UCLA Ophthalmic Oncology Center

Los Angeles, California, United States

Site Status

University of California-Los Angeles

Los Angeles, California, United States

Site Status

Ship Drug To : Kevin Kong- University of California, Irvine-Pharmacy

Orange, California, United States

Site Status

University of California, Irvine-Medical Center

Orange, California, United States

Site Status

Stanford University-Cancer Center

Palo Alto, California, United States

Site Status

UC Davis Cancer Center

Sacramento, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

UCSD Medical Center- Hillcrest

San Diego, California, United States

Site Status

Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Santa Monica, California, United States

Site Status

University of California, Los Angeles

Santa Monica, California, United States

Site Status

Redwood Regional Medical Group, Inc.

Santa Rosa, California, United States

Site Status

Drug Shipment: University of Colorado Cancer Center, Anschutz Cancer Pavilion

Aurora, Colorado, United States

Site Status

University of Colorado Denver (CTRC)

Aurora, Colorado, United States

Site Status

Unviersity of Colorado Hospital, Anschutz Cancer Pavilion

Aurora, Colorado, United States

Site Status

Unviersity of Colorado Hospital, Anschutz Inpatient Pavilion

Aurora, Colorado, United States

Site Status

Kaiser Permanente

Denver, Colorado, United States

Site Status

Kaiser Permanente

Lafayette, Colorado, United States

Site Status

Drug Shipping for Yale; C/O Thomas Ferencz, RPh, BCOP

New Haven, Connecticut, United States

Site Status

Smilow Cancer Hospital at Yale New Haven

New Haven, Connecticut, United States

Site Status

Clinical Trial Office

New Haven, Connecticut, United States

Site Status

Yale Cancer Center

New Haven, Connecticut, United States

Site Status

Memorial Cancer Institute

Hollywood, Florida, United States

Site Status

Cancer Center of South Florida Foundation, Inc.

Lake Worth, Florida, United States

Site Status

Memorial Cancer Institute (West)

Pembroke Pines, Florida, United States

Site Status

H Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

Site Status

Emory University Hospital Midtown

Atlanta, Georgia, United States

Site Status

Emory Clinic

Atlanta, Georgia, United States

Site Status

Emory University Clinic

Atlanta, Georgia, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

Winship Cancer Institution

Atlanta, Georgia, United States

Site Status

Georgia Cancer Specialists-Administrative Annex

Atlanta, Georgia, United States

Site Status

Georgia Cancer Specialists - Stemmer

Decatur, Georgia, United States

Site Status

Georgia Cancer Specialists-Macon

Macon, Georgia, United States

Site Status

Georgia Cancer Specialists-Kennestone

Marietta, Georgia, United States

Site Status

Georgia Cancer Specialists

Sandy Springs, Georgia, United States

Site Status

Cancer Research Center of Hawaii

Honolulu, Hawaii, United States

Site Status

Hawaii Medical Center East

Honolulu, Hawaii, United States

Site Status

OnCare Hawaii, Inc.

Honolulu, Hawaii, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Chicago Medical Center

Chicago, Illinois, United States

Site Status

Ingalls Memorial Hospital (Drug Shipment Only)

Harvey, Illinois, United States

Site Status

Ingalls Memorial Hospital

Harvey, Illinois, United States

Site Status

Monroe Medical Associates

Harvey, Illinois, United States

Site Status

Monroe Medical Associates

Tinley Park, Illinois, United States

Site Status

Indiana University Hospital

Indianapolis, Indiana, United States

Site Status

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Site Status

Ship Drug to: Investigational Drug Services

Indianapolis, Indiana, United States

Site Status

Wishard Memorial Hospital

Indianapolis, Indiana, United States

Site Status

Springmill Medical Clinic

Indianapolis, Indiana, United States

Site Status

Monroe Medical Associates

Munster, Indiana, United States

Site Status

The Community Hospital

Munster, Indiana, United States

Site Status

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

Site Status

Massachusette General Hospital

Boston, Massachusetts, United States

Site Status

Massachussetts General Hospital

Boston, Massachusetts, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Beth Isreal Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

DFCI/Pharmacy (Drug Shipment Only)

Boston, Massachusetts, United States

Site Status

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Lawrence and Idell Weisberg Cancer Treatment Center

Farmington Hills, Michigan, United States

Site Status

Siteman Cancer Center

City of Saint Peters, Missouri, United States

Site Status

Siteman Cancer Center- West County

Creve Coeur, Missouri, United States

Site Status

Barnes-Jewish Hospital

St Louis, Missouri, United States

Site Status

Washington University, School of Medicine

St Louis, Missouri, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

NSLIJ Health System/Monter Cancer Center

Lake Success, New York, United States

Site Status

Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavilion

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Site Status

Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians

Oneida, New York, United States

Site Status

Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians

Oswego, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians

Syracuse, New York, United States

Site Status

Investigational Drug Service, Pharmacy Department, UNC Hospitals

Chapel Hill, North Carolina, United States

Site Status

UNC Health Care, NC Cancer Hospital Infusion/lnpatient Pharmacy (CHIP)

Chapel Hill, North Carolina, United States

Site Status

UNC Hospitals

Chapel Hill, North Carolina, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

The Ohio State University Hospital East

Columbus, Ohio, United States

Site Status

The Ohio State University James Cancer Hospital and Solove Research Institute

Columbus, Ohio, United States

Site Status

James Care in Kenny

Columbus, Ohio, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute

Hershey, Pennsylvania, United States

Site Status

Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

Site Status

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center-Shadyside

Pittsburgh, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Vincent Armenio, MD

East Providence, Rhode Island, United States

Site Status

Pharma Resource

East Providence, Rhode Island, United States

Site Status

Tennessee Oncology, PLLC

Dickson, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Franklin, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Gallatin, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Hermitage, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Lebanon, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Murfreesboro, Tennessee, United States

Site Status

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Site Status

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Site Status

The Vanderbilt Cancer Clinic

Nashville, Tennessee, United States

Site Status

The Vanderbilt Chemo Pharmacy

Nashville, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Smyrna, Tennessee, United States

Site Status

The University of Texas

Houston, Texas, United States

Site Status

Swedish Cancer Institute

Seattle, Washington, United States

Site Status

Seattle Cancer Care Alliance

Seattle, Washington, United States

Site Status

Investigational Drug Service

Seattle, Washington, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

Sydney Cancer Centre

Camperdown, New South Wales, Australia

Site Status

Royal Adelaide Hospital, Department of Medical Oncology

Adelaide, South Australia, Australia

Site Status

Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology

East Melbourne, Victoria, Australia

Site Status

Department of Medical Oncology

Nedlands, Western Australia, Australia

Site Status

Nucleo de Oncologia da Bahia

Salvador, Estado de Bahia, Brazil

Site Status

Instituto Nacional de Câncer - INCA

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Associacao Hospital de Caridade de Ijui

Ijuí, Rio Grande do Sul, Brazil

Site Status

Irmandade da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Sao Lucas da PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Fundacao Pio XII Hospital de Cancer de Barretos

Barretos, São Paulo, Brazil

Site Status

Fundacao Hospital Amaral Carvalho

Jaú, São Paulo, Brazil

Site Status

Instituto do Câncer de São Paulo "Octavio Frias de Oliveira" - ICESP

São Paulo, São Paulo, Brazil

Site Status

Fundacao Antonio Prudente

São Paulo, São Paulo, Brazil

Site Status

UMBAL "Tsaritsa Yoanna - ISUL", Klinika po onkoterapiya

Sofia, Bulgaria, Bulgaria

Site Status

Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya

Sofia, Bulgaria, Bulgaria

Site Status

MDOZS Plovdiv EOOD; Parvo vatreshno himioterapevtichno otdelenie

Plovdiv, , Bulgaria

Site Status

MBAL Voennomeditsinska Academia, MMA HAT Sofia

Sofia, , Bulgaria

Site Status

MDOZS "Dr. Marko Markov", Otdelenie po onkoterapiya i paliativni grizhi

Varna, , Bulgaria

Site Status

Tom Baker Cancer Centre

Calgary, Alberta, Canada

Site Status

Alberta Health Services, Holy Cross Site

Calgary, Alberta, Canada

Site Status

Office of Dr. John McWhae

Calgary, Alberta, Canada

Site Status

Cross Cancer Institute

Edmonton, Alberta, Canada

Site Status

Dr. Georges-L. Dumont Regional Hospital

Moncton, New Brunswick, Canada

Site Status

Dr. Leon Richard Oncology Centre

Moncton, New Brunswick, Canada

Site Status

RSM Durham Regional Cancer Centre

Oshawa, Ontario, Canada

Site Status

Dr. Dana Blakolmer and Associates

Oshawa, Ontario, Canada

Site Status

The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

Site Status

Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, Canada

Site Status

Royal Victoria Hospital

Montreal, Quebec, Canada

Site Status

Montreal General Hospital

Montreal, Quebec, Canada

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

St. Mary's Hospital Center

Montreal, Quebec, Canada

Site Status

SUN Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

Site Status

Guangdong General Hospital

Guangzhou, Guangdong, China

Site Status

Nanjing Bayi Hospital

Nanjing, Jiangsu, China

Site Status

Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC

Beijing, , China

Site Status

307 Hospital of PLA

Beijing, , China

Site Status

Shanghai Chest Hospital/Department of Pulmonary Medicine

Shanghai, , China

Site Status

Shanghai Chest Hospital

Shanghai, , China

Site Status

Zhongshan Hospital Fudan University / Respiratory Department

Shanghai, , China

Site Status

Shanghai Pulmonary Hospital/Dept. of Oncology

Shanghai, , China

Site Status

Centre Francois Baclesse

Caen, , France

Site Status

Centre Georges-François Leclerc

Dijon, , France

Site Status

Hopital Albert Michallon

Grenoble, , France

Site Status

Pr Fabrice BARLESI

Marseille, , France

Site Status

Centre Antoine Lacassagne

Nice, , France

Site Status

Groupe Hospitalier Cochin

Paris, , France

Site Status

Hopital Tenon / Service de Pneumologie

Paris, , France

Site Status

Centre Rene Gauducheau / Service d'Oncologie Medicale

Saint-Herblain, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin

Cologne, , Germany

Site Status

Universitaetsklinik Carl-Gustav-Carus Dresden

Dresden, , Germany

Site Status

Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung

Essen, , Germany

Site Status

Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie

Großhansdorf, , Germany

Site Status

MVZ Prof. Mathey, Pfrof. Schofer GmbH

Hamburg, , Germany

Site Status

Thoraxklinik am Universitaetsklinikum Heidelberg, Internistische Onkologie der Thoraxtumoren

Heidelberg, , Germany

Site Status

Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie

München, , Germany

Site Status

Pius-Hospital Oldenburg

Oldenburg, , Germany

Site Status

HSK Dr.- Horst-Schmidt-Kliniken, Innere Medizin III Haematologie, Onkologie, Palliativmedizin

Wiesbaden, , Germany

Site Status

University General Hospital of Heraklion/ Department of Clinical Oncology

Heraklion, Crete, Greece

Site Status

General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department

Eksochi, Thessaloniki, Greece

Site Status

General Hospital of Chest Diseases of Athens "Sotiria"

Athens, , Greece

Site Status

Tuen Mun Hospital, Department of Clinical Oncology

Tuenmen, New Territories, Hong Kong

Site Status

Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital

Pokfulam, , Hong Kong

Site Status

Department of Clinical Oncology, Prince of Wales Hospital

Shatin, New Territories, , Hong Kong

Site Status

Orszagos Koranyi TBC és Pulmonologiai Intezet, VI. Bronchologia

Budapest, , Hungary

Site Status

Semmelweis Egyetem Pulmonologia Intezet

Budapest, , Hungary

Site Status

Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Tudogyogyaszati Klinika

Debrecen, , Hungary

Site Status

Veszprem Megyei Onkormanyzat Tudogyogyintezete

Farkasgyepű, , Hungary

Site Status

Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly

Székesfehérvár, , Hungary

Site Status

Pest Megyei Tudogyogyintezet, III. Osztaly

Törökbálint, , Hungary

Site Status

Aseptic Compounding Unit

Dublin, , Ireland

Site Status

Department of Medical Oncology

Dublin, , Ireland

Site Status

Department of Medical Oncology

Galway, , Ireland

Site Status

Merlin Park Imaging Centre

Galway, , Ireland

Site Status

Pharmacy Aseptic Service Unit

Galway, , Ireland

Site Status

A.O. di Rilievo Nazionale e di Alta Specialita - S. G. Moscati

Avellino, , Italy

Site Status

Azienda Ospedaliero-Universitaria Careggi

Florence, , Italy

Site Status

Oncologia Medica A

Genova, , Italy

Site Status

Ospedale Versilia, Oncologia Medica

Lido Di Camaiore (LU), , Italy

Site Status

Ospedale San Luca

Lucca, , Italy

Site Status

Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative

Milan, , Italy

Site Status

Istituto Europeo di Oncologia IRCCS

Milan, , Italy

Site Status

Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk

Milan, , Italy

Site Status

Nuovo Ospedale San Gerardo

Monza, , Italy

Site Status

Azienda Ospedaliera Universitaria San Luigi Gonzaga

Orbassano (TO), , Italy

Site Status

SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia

Perugia, , Italy

Site Status

Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani

Roma, , Italy

Site Status

Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette

Torino, , Italy

Site Status

Aichi cancer center central hospital

Nagoya, Aichi-ken, Japan

Site Status

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Site Status

National Kyushu Cancer Center

Fukuoka, Fukuoka, Japan

Site Status

National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, Japan

Site Status

Hyogo Cancer Center

Akashi, Hyōgo, Japan

Site Status

Okayama University Hospital

Okayama, Okayama-ken, Japan

Site Status

Kinki University Hospital

Osakasayama-shi, Osaka, Japan

Site Status

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

Site Status

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Site Status

The Cancer Institute Hospital of JFCR

Tokyo, , Japan

Site Status

Universitair Medisch Centrum Groningen

Groningen, , Netherlands

Site Status

Pracownia Optyczna Bozena Lawrynowicz Optyk Dyplomowany

Olsztyn, NAP, Poland

Site Status

Centrum Medyczne Ars Medica

Olsztyn, NAP, Poland

Site Status

Wojewodzki Szpital Specjalistyczny w Olsztynie

Olsztyn, NAP, Poland

Site Status

Pracownia Tomografii Komputerowej "ALL MEDI" Sp. z o.o.

Otwock, Poland, Poland

Site Status

Klinika Onkologii i Radioterapii

Gdansk, , Poland

Site Status

Uniwersyteckie Centrum Kliniczne

Gdansk, , Poland

Site Status

Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

Olsztyn, , Poland

Site Status

Centralna Izba Przyjec Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy

Otwock, , Poland

Site Status

Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii

Poznan, , Poland

Site Status

Zaklad Diagnostyki Obrazowej

Poznan, , Poland

Site Status

Lux Med. Sp.z o.o

Warsaw, , Poland

Site Status

Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic

Kazan', , Russia

Site Status

State Institution "National Cancer Research Center named after N.N. Blokhin' RAMS"

Moscow, , Russia

Site Status

City Clinical Oncology Dispensary

Saint Petersburg, , Russia

Site Status

Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav

Saint Petersburg, , Russia

Site Status

City Clinical Oncology Dispensary

Saint Petersburg, , Russia

Site Status

Research Institute of Pulmonology

Saint-Peterburg, , Russia

Site Status

State Medical Institution "Oncology Center #2" of Healthcare Department of Krasnodar Region

Sochi, , Russia

Site Status

National Cancer Center, Center for Lung Cancer

Goyang-si, Gyeonggi-do, South Korea

Site Status

Seoul National University Hospital / Department of Internal Medicine

Seoul, , South Korea

Site Status

Samsung MedicaCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine

Seoul, , South Korea

Site Status

Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera (Materno-Infantil)

A Coruña, A Coruña, Spain

Site Status

Hospital Universitari Germans Trias I Pujol

Badalona, Barcelona, Spain

Site Status

Hospital Del Mar

Barcelona, Barcelona, Spain

Site Status

Hospital General Universitari Vall D´Hebron

Barcelona, Barcelona, Spain

Site Status

Institut Catala Doncologia - Hospital Duran I Reynals

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Consorcio Hospitalario Parc Tauli

Sabadell, Barcelona, Spain

Site Status

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Universitario La Paz

Madrid, Madrid, Spain

Site Status

Hospital de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

Site Status

Hospital Universitario Virgen Del Rocio

Seville, Sevilla, Spain

Site Status

Karolinska Universitetssjukhuset, Onkologiska kliniken

Stockholm, , Sweden

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital, Department of Internal Medicine

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital, Chest Department

Taipei, , Taiwan

Site Status

Royal Marsden Hospital

Sutton, Surrey, United Kingdom

Site Status

The Alexandra Hospital

Cheshire, , United Kingdom

Site Status

Nuffield Health Wessex Hospital

Eastleigh, , United Kingdom

Site Status

Royal Free Hospital

London, , United Kingdom

Site Status

Kings College London at Guy's Hospital

London, , United Kingdom

Site Status

Royal Marsden Hospital

London, , United Kingdom

Site Status

Christie Hospital NHS Trust, Department of Medical Oncology

Manchester, , United Kingdom

Site Status

Cancer and Haematology Centre,

Oxford, , United Kingdom

Site Status

Southampton University Hospitals NHS Trust

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Bulgaria Canada China France Germany Greece Hong Kong Hungary Ireland Italy Japan Netherlands Poland Russia South Korea Spain Sweden Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Camidge DR, Kim EE, Usari T, Polli A, Lewis I, Wilner KD. Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC. J Thorac Oncol. 2019 Jun;14(6):1077-1085. doi: 10.1016/j.jtho.2019.02.015. Epub 2019 Feb 26.

Reference Type DERIVED
PMID: 30822515 (View on PubMed)

Wilner KD, Usari T, Polli A, Kim EE. Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer. Future Oncol. 2019 Apr;15(10):1097-1103. doi: 10.2217/fon-2018-0869. Epub 2019 Jan 17.

Reference Type DERIVED
PMID: 30652510 (View on PubMed)

Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS. Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clin Lung Cancer. 2017 Sep;18(5):472-479. doi: 10.1016/j.cllc.2017.03.004. Epub 2017 Mar 14.

Reference Type DERIVED
PMID: 28373069 (View on PubMed)

Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 Sep;17(5):e77-e94. doi: 10.1016/j.cllc.2016.03.005. Epub 2016 Mar 30.

Reference Type DERIVED
PMID: 27130468 (View on PubMed)

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crino L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.

Reference Type DERIVED
PMID: 25624436 (View on PubMed)

Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014 Nov;9(11):1720-5. doi: 10.1097/JTO.0000000000000326.

Reference Type DERIVED
PMID: 25436806 (View on PubMed)

Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

Reference Type DERIVED
PMID: 23724913 (View on PubMed)

Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013 Jan 1;31(1):e15-7. doi: 10.1200/JCO.2012.43.3730. Epub 2012 Nov 19. No abstract available.

Reference Type DERIVED
PMID: 23169500 (View on PubMed)

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-012595-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

A8081007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.